tiprankstipranks
Xenon Pharmaceuticals (XENE)
NASDAQ:XENE
US Market
XENE
Xenon
RESEARCH TOOLSreports
Want to see XENE full AI Analyst Report?

Xenon (XENE) Stock Forecast & Price Target

468 Followers
See the Price Targets and Ratings of:

XENE Analyst Ratings

Strong Buy
11Ratings
Strong Buy
11 Buy
0 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Xenon
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

XENE Stock 12 Month Forecast

Average Price Target

$75.77
▲(26.91% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Xenon in the last 3 months. The average price target is $75.77 with a high forecast of $86.00 and a low forecast of $63.00. The average price target represents a 26.91% change from the last price of $59.70.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","58":"$58","87":"$87","43.5":"$43.5","72.5":"$72.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":86,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$86.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75.765,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$75.77</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":63,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$63.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,43.5,58,72.5,87],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.41,55.91692307692308,58.42384615384615,60.93076923076923,63.4376923076923,65.94461538461539,68.45153846153846,70.95846153846153,73.46538461538461,75.9723076923077,78.47923076923077,80.98615384615385,83.49307692307693,{"y":86,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.41,55.129615384615384,56.849230769230765,58.56884615384615,60.28846153846153,62.00807692307692,63.72769230769231,65.44730769230769,67.16692307692307,68.88653846153846,70.60615384615384,72.32576923076923,74.04538461538462,{"y":75.765,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.41,54.1476923076923,54.88538461538461,55.62307692307692,56.36076923076923,57.098461538461535,57.83615384615384,58.573846153846155,59.31153846153846,60.04923076923077,60.786923076923074,61.52461538461539,62.262307692307694,{"y":63,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":30.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.09,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.3,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.12,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.92,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.51,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.82,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.55,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.69,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.41,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$86.00Average Price Target$75.77Lowest Price Target$63.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on XENE
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$50→$63
Buy
5.53%
Upside
Reiterated
06/22/26
Leerink Partners Sticks to Its Buy Rating for Xenon (XENE)
Wells Fargo Analyst forecast on XENE
Benjamin Burnett
Wells Fargo
Wells Fargo
$69
Buy
15.58%
Upside
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)
J.P. Morgan Analyst forecast on XENE
Tessa Romero
J.P. Morgan
J.P. Morgan
$80→$82
Buy
37.35%
Upside
Assigned
05/27/26
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorganXenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
William Blair Analyst forecast on XENE
Myles Minter
William Blair
William Blair
$80.65
Buy
35.09%
Upside
Reiterated
05/08/26
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
H.C. Wainwright Analyst forecast on XENE
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$53→$74
Buy
23.95%
Upside
Reiterated
05/08/26
H.C. Wainwright Remains a Buy on Xenon (XENE)
Evercore ISI Analyst forecast on XENE
Cory Kasimov
Evercore ISI
Evercore ISI
$55→$80
Buy
34.00%
Upside
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Xenon (XENE)
Stifel Nicolaus Analyst forecast on XENE
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$89→$86
Buy
44.05%
Upside
Reiterated
05/08/26
Xenon (XENE) Gets a Buy from Stifel Nicolaus
Wedbush Analyst forecast on XENE
Laura Chico
Wedbush
Wedbush
$63
Buy
5.53%
Upside
Reiterated
05/08/26
Wedbush Reaffirms Their Buy Rating on Xenon (XENE)
Needham Analyst forecast on XENE
Serge Belanger
Needham
Needham
$80→$78
Buy
30.65%
Upside
Reiterated
05/08/26
Needham Reaffirms Their Buy Rating on Xenon (XENE)
TD Cowen Analyst forecast on XENE
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on XENE
Brian Abrahams
RBC Capital
RBC Capital
$80→$82
Buy
37.35%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Lifestance Health Group (NASDAQ: LFST), Gilead Sciences (NASDAQ: GILD) and Xenon (NASDAQ: XENE)
Deutsche Bank Analyst forecast on XENE
David Hoang
Deutsche Bank
Deutsche Bank
$56→$90
Buy
50.75%
Upside
Reiterated
03/10/26
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche BankXenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
Goldman Sachs Analyst forecast on XENE
Paul Choi
Goldman Sachs
Goldman Sachs
$52→$75
Buy
25.63%
Upside
Reiterated
03/10/26
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman SachsXenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
Guggenheim Analyst forecast on XENE
Yatin Suneja
Guggenheim
Guggenheim
$60→$90
Buy
50.75%
Upside
Reiterated
03/09/26
Xenon Pharmaceuticals price target raised to $90 from $60 at GuggenheimXenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
Bank of America Securities Analyst forecast on XENE
Jason Gerberry
Bank of America Securities
Bank of America Securities
$50→$77
Buy
28.98%
Upside
Reiterated
03/09/26
Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on XENE
Unknown Analyst
Leerink Partners
Not Ranked
Leerink Partners
$50→$63
Buy
5.53%
Upside
Reiterated
06/22/26
Leerink Partners Sticks to Its Buy Rating for Xenon (XENE)
Wells Fargo Analyst forecast on XENE
Benjamin Burnett
Wells Fargo
Wells Fargo
$69
Buy
15.58%
Upside
Reiterated
06/01/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Mirum Pharmaceuticals (NASDAQ: MIRM) and Corbus Pharmaceuticals (NASDAQ: CRBP)
J.P. Morgan Analyst forecast on XENE
Tessa Romero
J.P. Morgan
J.P. Morgan
$80→$82
Buy
37.35%
Upside
Assigned
05/27/26
Xenon Pharmaceuticals price target raised to $82 from $80 at JPMorganXenon Pharmaceuticals price target raised to $82 from $80 at JPMorgan
William Blair Analyst forecast on XENE
Myles Minter
William Blair
William Blair
$80.65
Buy
35.09%
Upside
Reiterated
05/08/26
Analyst Reaffirms Buy on Xenon, Citing Blockbuster Potential for Lead Epilepsy Candidate and Upside from Pipeline Programs
H.C. Wainwright Analyst forecast on XENE
Douglas Tsao
H.C. Wainwright
H.C. Wainwright
$53→$74
Buy
23.95%
Upside
Reiterated
05/08/26
H.C. Wainwright Remains a Buy on Xenon (XENE)
Evercore ISI Analyst forecast on XENE
Cory Kasimov
Evercore ISI
Evercore ISI
$55→$80
Buy
34.00%
Upside
Reiterated
05/08/26
Evercore ISI Sticks to Their Buy Rating for Xenon (XENE)
Stifel Nicolaus Analyst forecast on XENE
Paul Matteis
Stifel Nicolaus
Stifel Nicolaus
$89→$86
Buy
44.05%
Upside
Reiterated
05/08/26
Xenon (XENE) Gets a Buy from Stifel Nicolaus
Wedbush Analyst forecast on XENE
Laura Chico
Wedbush
Wedbush
$63
Buy
5.53%
Upside
Reiterated
05/08/26
Wedbush Reaffirms Their Buy Rating on Xenon (XENE)
Needham Analyst forecast on XENE
Serge Belanger
Needham
Needham
$80→$78
Buy
30.65%
Upside
Reiterated
05/08/26
Needham Reaffirms Their Buy Rating on Xenon (XENE)
TD Cowen Analyst forecast on XENE
Joseph Thome
TD Cowen
TD Cowen
―
Buy
―
Reiterated
05/07/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
RBC Capital Analyst forecast on XENE
Brian Abrahams
RBC Capital
RBC Capital
$80→$82
Buy
37.35%
Upside
Reiterated
05/07/26
Analysts Offer Insights on Healthcare Companies: Lifestance Health Group (NASDAQ: LFST), Gilead Sciences (NASDAQ: GILD) and Xenon (NASDAQ: XENE)
Deutsche Bank Analyst forecast on XENE
David Hoang
Deutsche Bank
Deutsche Bank
$56→$90
Buy
50.75%
Upside
Reiterated
03/10/26
Xenon Pharmaceuticals price target raised to $90 from $56 at Deutsche BankXenon Pharmaceuticals price target raised to $90 from $56 at Deutsche Bank
Goldman Sachs Analyst forecast on XENE
Paul Choi
Goldman Sachs
Goldman Sachs
$52→$75
Buy
25.63%
Upside
Reiterated
03/10/26
Xenon Pharmaceuticals price target raised to $75 from $52 at Goldman SachsXenon Pharmaceuticals price target raised to $75 from $52 at Goldman Sachs
Guggenheim Analyst forecast on XENE
Yatin Suneja
Guggenheim
Guggenheim
$60→$90
Buy
50.75%
Upside
Reiterated
03/09/26
Xenon Pharmaceuticals price target raised to $90 from $60 at GuggenheimXenon Pharmaceuticals price target raised to $90 from $60 at Guggenheim
Bank of America Securities Analyst forecast on XENE
Jason Gerberry
Bank of America Securities
Bank of America Securities
$50→$77
Buy
28.98%
Upside
Reiterated
03/09/26
Bank of America Securities Keeps Their Buy Rating on Xenon (XENE)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Xenon

3 Months
Tessa RomeroJ.P. Morgan
Success Rate
9/13 ratings generated profit
69%
Average Return
+11.91%
Copying Tessa Romero's trades and holding each position for 3 Months would result in 69.23% of your transactions generating a profit, with an average return of +11.91% per trade.
1 Year
Andrew TsaiJefferies
Success Rate
15/18 ratings generated profit
83%
Average Return
+38.57%
Copying Andrew Tsai's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +38.57% per trade.
2 Years
Tessa RomeroJ.P. Morgan
Success Rate
12/13 ratings generated profit
92%
Average Return
+30.58%
Copying Tessa Romero's trades and holding each position for 2 Years would result in 92.31% of your transactions generating a profit, with an average return of +30.58% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

XENE Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
2
4
5
5
3
Buy
29
37
33
28
13
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
41
38
33
16
In the current month, XENE has received 16 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. XENE average Analyst price target in the past 3 months is 75.77.
Each month's total comprises the sum of three months' worth of ratings.

XENE Financial Forecast

XENE Earnings Forecast

Next quarter’s earnings estimate for XENE is -$1.14 with a range of -$1.46 to -$0.92. The previous quarter’s EPS was -$1.17. XENE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.
Next quarter’s earnings estimate for XENE is -$1.14 with a range of -$1.46 to -$0.92. The previous quarter’s EPS was -$1.17. XENE beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.

XENE Sales Forecast

Next quarter’s sales forecast for XENE is $1.67M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $0.00. XENE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.
Next quarter’s sales forecast for XENE is $1.67M with a range of $0.00 to $15.00M. The previous quarter’s sales results were $0.00. XENE beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year XENE has Performed in-line its overall industry.

XENE Stock Forecast FAQ

What is XENE’s average 12-month price target, according to analysts?
Based on analyst ratings, Xenon Pharmaceuticals’s 12-month average price target is 75.77.
    What is XENE’s upside potential, based on the analysts’ average price target?
    Xenon Pharmaceuticals has 26.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is XENE a Buy, Sell or Hold?
          Xenon Pharmaceuticals has a consensus rating of Strong Buy which is based on 11 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Xenon Pharmaceuticals’s price target?
            The average price target for Xenon Pharmaceuticals is 75.77. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $86.00 ,the lowest forecast is $63.00. The average price target represents 26.91% Increase from the current price of $59.7.
              What do analysts say about Xenon Pharmaceuticals?
              Xenon Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of XENE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.